^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Jiataile (sacituzumab tirumotecan)

    i
    Other names: SKB-264, MK2870, MK 2870, MK-2870, SKB 264, SKB264, sac-TMT
    Company:
    Merck (MSD), Sichuan Kelun Pharma
    Drug class:
    Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate
    Related drugs:
    8d
    PROTECT-2: Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=49, Recruiting, The First Affiliated Hospital of Xiamen University | Not yet recruiting --> Recruiting | Trial completion date: May 2027 --> Dec 2027 | Initiation date: Jun 2025 --> Dec 2025 | Trial primary completion date: Jun 2026 --> Mar 2027
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    |
    EGFR mutation
    |
    Cosela (trilaciclib) • Jiataile (sacituzumab tirumotecan)
    9d
    Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP) (clinicaltrials.gov)
    P2, N=68, Not yet recruiting, National Cancer Centre, Singapore
    New P2 trial
    |
    TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    Jiataile (sacituzumab tirumotecan)
    16d
    Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/Rectum (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    CD4 (CD4 Molecule)
    |
    Jiataile (sacituzumab tirumotecan)
    22d
    TroFuse-031: A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) (clinicaltrials.gov)
    P3, N=590, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    paclitaxel • docetaxel • Jiataile (sacituzumab tirumotecan) • Javlor (vinflunine)
    23d
    SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer (clinicaltrials.gov)
    P2, N=89, Recruiting, Fujian Cancer Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Jiataile (sacituzumab tirumotecan) • Qibeian (iparomlimab/tuvonralimab)
    23d
    Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC): A Prospective, Single-Arm, Phase II Study(STAR-01) (clinicaltrials.gov)
    P2, N=33, Not yet recruiting, Sichuan University
    New P2 trial
    |
    Focus V (anlotinib) • Jiataile (sacituzumab tirumotecan)
    26d
    A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (clinicaltrials.gov)
    P3, N=770, Recruiting, Merck Sharp & Dohme LLC | N=251 --> 770
    Enrollment change • Platinum sensitive
    |
    Avastin (bevacizumab) • dexamethasone • Jiataile (sacituzumab tirumotecan)
    28d
    Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Feb 2028 --> Jun 2028
    Trial primary completion date
    |
    SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1)
    |
    Jiataile (sacituzumab tirumotecan)
    1m
    A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (clinicaltrials.gov)
    P3, N=251, Recruiting, Merck Sharp & Dohme LLC
    New P3 trial • Platinum sensitive
    |
    Avastin (bevacizumab) • dexamethasone • Jiataile (sacituzumab tirumotecan)
    1m
    A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) (clinicaltrials.gov)
    P1/2, N=190, Recruiting, Merck Sharp & Dohme LLC | N=57 --> 190
    Enrollment change • Trial initiation date
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • patritumab deruxtecan (U3-1402) • Jiataile (sacituzumab tirumotecan) • calderasib (MK-1084)
    1m
    TroFuse-009: Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (clinicaltrials.gov)
    P3, N=520, Recruiting, Merck Sharp & Dohme LLC | N=100 --> 520
    Enrollment change
    |
    carboplatin • pemetrexed • dexamethasone • Jiataile (sacituzumab tirumotecan)
    1m
    Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=45, Recruiting, Fudan University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Trodelvy (sacituzumab govitecan-hziy) • Datroway (datopotamab deruxtecan-dlnk) • Jiataile (sacituzumab tirumotecan)